Azathioprine prednisone treatment idiopathic pulmonary fibrosis prospective double-blind placebo-controlled clinical trial Twenty-seven patients idiopathic pulmonary fibrosis IPF IPF prospective double-blind placebo-controlled study therapeutic effect combined prednisone/azathioprine prednisone placebo Prednisone mg/kg/day mg/day first wk biweekly taper maintenance dose mg/day Azathioprine daily dose mg/kg mg/day patients use azathioprine well side effects Changes lung function yr alveolar-arterial oxygen difference A-a FVC single breath diffusing capacity carbon monoxide DLCOSB azathioprine/prednisone group prednisone group none comparisons significant Six patients plus azathioprine follow-up period patients plus placebo Cox model survival analysis nonsignificant large survival advantage azathioprine/prednisone hazard ratio confidence interval age survival advantage azathioprine/prednisone significant hazard ratio confidence interval large sample approximation randomization test prednisone azathioprine safe effective regimen treatment IPF 